干细胞对急性心肌梗死后心肌修复的研究进展

摘要/Abstract

摘要： 目前对于急性心肌梗死的治疗,主要采用药物溶栓、冠脉介入和心脏搭桥手术等方法,开通闭塞血管,恢复心肌再灌注,进而改善心肌缺血挽救濒死心肌.然而这些方法对已坏死心肌却无再生作用,最终导致缺血性心肌病的发生.最初研究显示,干细胞具有再生心肌、提高左室功能的作用,为实现心肌的有效再生带来曙光.然而随着研究的深入,干细胞的心肌再生只在动物模型中被发现,且数量极少.从临床角度来看,干细胞移植后有多种因素促进了心功能的恢复,因此心肌再生的概念已被心肌修复所替代.现就干细胞对心肌的修复作用作一综述.

关键词: 干细胞, 心肌梗死, 再生, 修复, 组织工程

Abstract: For the therapy of acute myocardial infarction, the main methods are pharmacological thrombolysis, percutaneous coronary intervention and cardiac bypass operation, opening the occluded vessel, recovery of myocardial reperfusion, further improving myocardial blood supply and saving dying myocardium. But all the methods can not generate new myocardiums, eventually lead to the occurrence of ischemic cardiomyopathy. Initial studies show stem cells could regenerate lost cardiomyocytes and improve left ventricular function, for realizing the effective myocardial regeneration bings hope. However, with the development of the research, the evidence for true generation of new myocardium is confined to the experimental models, and the number is very few. In the clinical perspective, myocardial regeneration has been replaced by myocardial repair, as other mechanisms seem to be involved heart function recovery. In this review, we will focus on stem cells for cardiac repair.

Key words: stem cells, myocardial infarction, regeneration, repair, tissue engineering

中图分类号:

R542.2

瞿海龙,边剑飞,周英莲,麻晓静,彭广军. 干细胞对急性心肌梗死后心肌修复的研究进展[J]. 医学研究与教育, 2012, 29(6): 60-64.

参考文献

[1] 武金霞, 单彪, 习洋, 甄兴航, 张贺迎, WU Jin-xia, SHAN Biao, XI Yang, ZHEN Xin-hang, ZHANG He-ying. 蚯蚓冻干粉的抗氧化作用 [J]. 河北大学学报（自然科学版） 2010.doi:10.3969/j.issn.1000-1565.2010.01.016
[2] 张娜, 郭圣荣, ZHANG Na, GUO Sheng-rong. 双嘧达莫嵌段共聚物胶束的制备及体外药物释放 [J]. 河北大学学报（自然科学版） 2010.doi:10.3969/j.issn.1000-1565.2010.06.012
[3] 瞿海龙, 麻晓静, 张冰. 干细胞治疗自身免疫性疾病和心脏疾患的研究进展 [J]. 医学研究与教育 2011.doi:10.3969/j.issn.1674-490X.2011.02.024
[4] Evidence for Cardiomyocyte Renewal in Humans [J]. Science 2009, Apr.3 TN.5923(Apr.3 TN.5923).
[5] Kajstura J, Gurusamy N, Ogorek B, Goichberg P, Clavo Rondon C, Hosoda T, D'Amario D, Bardelli S, Beltrami AP, Cesselli D, Bussani R, del Monte F, Quaini F, Rota M, Beltrami CA, Buchholz BA, Leri A, Anversa P. Myocyte turnover in the aging human heart. [J]. Circulation research: a journal of the American Heart Association 2010, 11(11).
[6] LANDMESSER U, ENGBERDING N, BAHLMANN F H. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase [J]. Circulation 2004, 110(14).
[7] Zohlnhofer D, Dibra A, Koppara T, de-Waha A, Ripa RS, Kastrup J, Valgimigli M, Schomig A, Kastrati A. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. [J]. Journal of the American College of Cardiology 2008, 15(15).
[8] HENRY T D, ANNEX B H, MCKENDALL G R. The VIVA trial:vascular endothelial growth factor in ischemia for vascular angiogenesis [J]. Circulation 2003, 107(10).
[9] KASTRUP J, JORGENSEN E, RUCK A. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study:the euroinject one trial [J]. Journal of the American College of Cardiology 2005, 45(07).
[10] Menard C, Hagege AA, Agbulut O, Barro M, Morichetti MC, Brasselet C, Bel A, Messas E, Bissery A, Bruneval P, Desnos M, Puceat M, Menasche P. [J]. The Lancet 2005.
[11] Ahmed RP, Ashraf M, Buccini S, Shujia J, Haider HKh. Cardiac tumorigenic potential of induced pluripotent stem cells in an immunocompetent host with myocardial infarction. [J]. Regenerative medicine 2011, 2(2).
[12] de-la-Grandmaison GL, Clairand I, Durigon M. [J]. Forensic science international 2001.
[13] Schachinger V, Aicher A, Dobert N, Rover R, Diener J, Fichtlscherer S, Assmus B, Seeger FH, Menzel C, Brenner W, Dimmeler S, Zeiher AM. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. [J]. Circulation: An Official Journal of the American Heart Association 2008, 14(14).
[14] Arminan A, Gandia C, Garcia Verdugo JM, Lledo E, Trigueros C, Ruiz Sauri A, Minana MD, Solves P, Paya R, Montero JA, Sepulveda P. Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction. [J]. Journal of the American College of Cardiology 2010, 20(20).
[15] Murry CE, Reinecke H, Pabon LM. [J]. Journal of the American College of Cardiology 2006.
[16] Bel A, Planat Bernard V, Saito A, Bonnevie L, Bellamy V, Sabbah L, Bellabas L, Brinon B, Vanneaux V, Pradeau P, Peyrard S, Larghero J, Pouly J, Binder P, Garcia S, Shimizu T, Sawa Y, Okano T, Bruneval P, Desnos M, Hagege AA, Casteilla L, Puceat M, Menasche P. Composite cell sheets: a further step toward safe and effective myocardial regeneration by cardiac progenitors derived from embryonic stem cells. [J]. Circulation: An Official Journal of the American Heart Association 2010, 11 Suppl.1(11 Suppl.1).
[17] Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun Prieto L, Delafontaine P, Prockop DJ. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. [J]. Cell stem cell 2009, 1(1).
[18] Hare JM, Traverse JH, Henry T. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. [J]. Journal of the American College of Cardiology 2009, 24(24).
[19] Hare JM, Traverse JH, Henry T. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. [J]. Journal of the American College of Cardiology 2009, 24(24).
[20] BARTUNEK J, WIJNS W, DOLATABADI D. C-CURE multicenter trial:lineage specified bone marrow derived cardiopoietic mesenchymal stem cells for treatment of ischemic cardiomyopathy [J]. Journal of the American College of Cardiology 2011, 57(14 Suppl 1).
[21] ORLIC D, KAJSTURA J, CHIMENTI S. Bone marrow cells regenerate infarcted myocardium [J]. Nature 2001, 410(6829).
[22] STRAUER B E, BREHM M, ZEUS T. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans [J]. Circulation 2002, 106(15).
[23] Meyer GP, Wollert KC, Lotz. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. [J]. European Heart Journal 2009, 24(24).
[24] Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. [J]. The New England journal of medicine 2006, 12(12).
[25] Penicka M, Horak J, Kobylka P, Pytlik R, Kozak T, Belohlavek O, Lang O, Skalicka H, Simek S, Palecek T, Linhart A, Aschermann M, Widimsky P. [J]. Journal of the American College of Cardiology 2007.
[26] Wohrle J, Merkle N, Mailander V, Nusser T, Schauwecker P, von Scheidt F, Schwarz K, Bommer M, Wiesneth M, Schrezenmeier H, Hombach V. [J]. The American Journal of Cardiology 2010.